Macrophage Activation Syndrome
📧 Sign up to get email alerts when something new happens for Macrophage Activation Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE [Phase 3]
A Phase 3 clinical trial evaluated the efficacy, safety, tolerability, and pharmacokinetics/pharmacodynamics of emapalumab in children and a…
-
CLINICAL_TRIALS trial_result · 2026-01-22Clinical Trial Update: Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis [NA]
This clinical trial update characterizes the inflammatory profile of patients with macrophage activation syndrome (MAS) secondary to bacteri…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Assessment of Macrophage Activation syndromE in STill's Disease in Italy
A clinical trial evaluating macrophage activation syndrome in Still's disease (systemic juvenile idiopathic arthritis and adult-onset Still'…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Assessment of Macrophage Activation syndromE in STill's Disease
A completed clinical trial assessing macrophage activation syndrome in Still's disease, including adult-onset Still's disease and juvenile-o…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: Treatment of Macrophage Activation Syndrome (MAS) With Anakinra [Phase 1]
A Phase 1 trial evaluating anakinra for macrophage activation syndrome has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-03-17Clinical Trial Update: Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome [Phase 3]
Phase 3 trial investigating ruxolitinib with methylprednisolone as first-line treatment for macrophage activation syndrome.
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) [Phase 2]
Phase 2 study evaluating safety and efficacy of emapalumab (anti-IFN-gamma) in patients with systemic juvenile idiopathic arthritis or adult…
-
CLINICAL_TRIALS trial_result · 2020-07-29Clinical Trial Update: A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis [Phase 2]
Phase 2 clinical trial update for validation and restoration of immune dysfunction in severe infections and sepsis has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-06Clinical Trial Update: Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） [Phase 1, Phase 2]
A clinical trial update on low-dose Interleukin-2 treatment for Macrophage Activation Syndrome (Phase 1/Phase 2), with status not disclosed.